Long-term Preservation of Left Ventricular Function and Heart Failure Incidence with Ablate and Pace Therapy Utilizing Biventricular Pacing
|
|
- Marylou Dawson
- 5 years ago
- Views:
Transcription
1 The Journal of Innovations in Cardiac Rhythm Management, 3 (2012), HEART FAILURE RESEARCH ARTICLE Long-term Preservation of Left Ventricular Function and Heart Failure Incidence with Ablate and Pace Therapy Utilizing Biventricular Pacing 1,2 RAHUL N. DOSHI, MD, 1 NIKHIL GUPTA, BSc, 1 NATASHA DOSHI, 1 DANIEL LANDA, MD, 1 PAUL WEINSTEIN, MD, 1 DAVID WEINBERG, MD, 1 FRANK BONAVITA, MD and 1 CHRISTINA CASILLAS 1 Fullerton Cardiovascular Medical Group, Fullerton, CA 2 University of California Irvine, Irvine, CA ABSTRACT. Ablate and pace therapy has been utilized to improve symptoms in patients with symptomatic atrial fibrillation (AF) but requires dedicated ventricular pacing. Biventricular (BiV) pacing may eliminate the potential negative consequences of dedicated right ventricular (RV) pacing. We reviewed 245 patients who were considered at risk for congestive heart failure (CHF) with preserved left ventricular ejection fraction (LVEF) and underwent ablate and pace therapy with a BiV pacemaker. A total of 225 patients had follow-up greater than 1 year, and 175 patients had echocardiogram data prior to the procedure. Follow-up echocardiograms were obtained. Patients were assessed whether they were predominantly in sinus rhythm (SR) or AF. Patients were screened for CHF admissions during the follow-up period. All 245 patients had successful implantation without significant complications. The mean follow-up was months. LVEF remained preserved over the follow-up period (53 12% pre-ablation and 58 11% post ablation). Patients in SR showed a significant improvement in LVEF, whereas the mild improvement in patients in AF did not reach statistical significance. The 1-year survival rate of the total population at 1, 3, and 5 years is 97.4%, 87.6%, and 78.0%, respectively. The CHF hospitalization-free rates at 1, 3, and 5 years are 100%, 96.8%, and 92.7%, respectively. Ablate and pace therapy with BiV pacing results in long-term preservation in LVEF with a low incidence of heart failure in patients with preserved left ventricular function at risk for heart failure. A large-scale randomized clinical trial is warranted to determine if this approach should be widely utilized. KEYWORDS. ablate and pace, atrial fibrillation, biventricular pacing, heart failure. ISSN (print) ISSN (online) 2012 Innovations in Cardiac Rhythm Management Introduction Ablate and pace therapy have been demonstrated to effectively improve symptoms of atrial fibrillation (AF) and improve exercise tolerance. 1 Biventricular (BiV) pacing has been utilized to prevent the negative effects The authors report no conflicts of interest for the published content. Manuscript received August 11, 2012, final version accepted September 4, Address correspondence to: Rahul N. Doshi, MD, Fullerton Cardiovascular Medical Group, 2240 N. Harbor Blvd Suite 200, Fullerton, CA rdoshi@fullertonheart.com of committed pacing in this population. 2 4 The Left Ventricular-Based Cardiac Stimulation Post AV Nodal Ablation Evaluation (PAVE) study demonstrated that BiV pacing results in the preservation of left ventricular (LV) function in patients undergoing atrioventricular nodal (AVN) ablation when compared with right ventricular (RV) pacing at 6 months. 2 Similarly, the Ablate and Pace in Atrial Fibrillation (APAF) trial demonstrated in a population of 186 patients with symptomatic persistent AF that BiV pacing shows preservation of left ventricular ejection fraction (LVEF) over a longer follow-up with a mean duration of 20 The Journal of Innovations in Cardiac Rhythm Management, October
2 R N Doshi, N Gupta, N Doshi, et al. months. 3 However, roughly half the patients had severe LV dysfunction (mean LVEF 37%) requiring defibrillator therapy. 3 The Pacing to Avoid Cardiac Enlargement (PACE) study demonstrated that patients with preserved LV function and sinus rhythm (SR) had improved LV function with a BiV pacemaker compared with RV apical pacing at 1 year. 4 Thus, preservation of LVEF is seen in patients with SR or persistent AF who have dedicated ventricular pacing over 1 year and perhaps longer. Conversely, Zhang and colleagues 5 described patients with new RV apical pacing for complete heart block and preserved LV function having a high risk of congestive heart failure (CHF), especially elderly patients, those with coronary disease or myocardial infarction, AF, or a wide paced QRS complex. It is still controversial whether dedicated RV pacing in the ablate and pace population leads to deleterious effects and whether this population should instead receive a BiV pacemaker. Whether there is long-term (.1 year) preservation of LVEF in the normal LVEF population with AF and prior AVN ablation has not yet been demonstrated. It has been our practice to employ BiV pacing when performing ablate and pace therapy in our patients who are elderly and otherwise have demonstrated or are considered at risk for CHF, regardless of baseline LV function. We reviewed our patient population of ablate and pace therapy with BiV pacing and preserved LVEF to determine the long-term effects on LV function and incidence of heart failure admissions. Methods We performed a retrospective chart review of 245 patients who underwent ablate and pace therapy with BiV pacemaker implantation at our institution between July 2005 and December 2011 and had maintained follow-up in our pacemaker clinic. Patients had either paroxysmal or persistent AF and symptomatic palpitations, dyspnea, or precipitation of heart failure with Table 1: Baseline implant demographics (N5245) N (%) Age (years) 77 9 Male 154 (63) Prior CHF 64 ((26) HTN 101 (41) CAD 45 (18) Valve disease 39 (16) COPD 24 (10) DM 25 (10) Predominant rhythm Atrial fibrillation 128 (52) Sinus rhythm 117 (48) AAD drug use Amiodarone 61 (25) Other AAD 21 (8) Warfarin 156 (64) AAD: CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; HTN: Table 2: Implant results (N5245) N (%) Time implant (min) Time fluoroscopy (min) Complications Pneumothorax 0 (0) Hematoma 3 (1.2) Cardiac tamponade 0 (0) Lead dislodgement 3 (1.2) Infection 0 (0) Phrenic nerve stimulation 14 (5.7) (requiring revision) 0 (0) rapid AF. All patients had relatively preserved LV function (LVEF.45%) at the time of implantation and were considered high risk for developing heart failure (prior heart failure, hypertensive heart disease, coronary artery disease, valvular heart disease, diabetes mellitus, or age >75). 5 Patients were not excluded if they had prior catheter ablation for AF. Medical records were examined for heart failure symptoms/admissions and mortality. Patients were also contacted to determine whether they had been hospitalized for heart failure at another institution. Subjects were then screened for both continued follow-up and the presence of echocardiographic data prior to implantation. A total of 20 patients were lost to follow-up, leaving 225 patients for analysis. A total of 175 patients had echocardiographic data available prior to the procedure. A repeat echocardiogram was then obtained to complete the follow-up. Echocardiograms performed during the follow-up period were not included for analysis. Patients were also separated into predominantly SR (programmed in a DDDR mode) and persistent/permanent AF (programmed in a VVIR mode). Table 3: Patient demographics.1 year follow-up (N5175) N (%) Mean follow-up (months) 37 18* Age (years) 77 9* Male 109 (62)* Prior CHF 43 (25)* HTN 86 (49)* CAD 39 (22)* Valve disease 31 (18)* COPD 21 (12)* DM 20 (11)* Predominant rhythm Sinus rhythm 85 (49)* Atrial fibrillation 90 (51)* AAD drug use Amiodarone 46 (26)* Other AAD 15 (8.6)* Warfarin 126 (72)* AAD: CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; HTN: *P5NS compared to total implant group. 977 The Journal of Innovations in Cardiac Rhythm Management, October 2012
3 Preservation LVEF and CHF with Ablate and Pace and BiV Pacing Table 4: Predominant sinus rhythm versus atrial fibrillation SR group N585 (%) AF group N590 (%) Mean follow-up (months) Age (years) Male 57 (67) 52 (58) CHF 23 (27) 20 (22) HTN 40 (47) 46 (51) CAD 22 (26) 17 (19) Valve disease 15 (18) 16 (18) COPD 7 (8.2) 14 (16) DM 11 (15) 9 (10) AAD medications Amiodarone 29 (39) 17 (19)* Other AAD 11 (15) 4 (4.4) Warfarin 46 (61) 79 (88)* AAD: AF: atrial fibrillation; CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; HTN: SR: sinus rhythm. *p,0.05. All data were analyzed utilizing Microsoft Excel (Microsoft, Seattle, WA). Statistical comparisons were made using the Student s t-test (two tails, equal variance). Kaplan Meier survival and event-free estimates were generated on Microsoft Excel (Microsoft, Seattle, WA). Results The baseline patient characteristics of the 245 patients who underwent implantation with a BiV pacer with AVN ablation are shown in Table 1. The patients were elderly (mean age 77 9 years), and the majority were male (63%). The populations were fairly balanced between those in AF Figure 1: Left ventricular ejection fraction pre- and post atrioventricular nodal ablation, mean follow-up months, N5175. The Journal of Innovations in Cardiac Rhythm Management, October
4 R N Doshi, N Gupta, N Doshi, et al. Figure 2: Left ventricular ejection fraction pre- and post atrioventricular nodal ablation, sinus rhythm group (N585) versus atrial fibrillation group (N590). and predominantly SR (52% and 48%, respectively). Twenty-six percent of patients had prior heart failure. The most common comorbidity was hypertension (41%). The acute implant results are given in Table 2. All 245 patients were successfully implanted with a mean time of implantation of min. There were three lead dislodgements requiring lead revision during the same hospital stay (two atrial lead dislodgements, one LV lead dislodgement). The most frequent complication was phrenic nerve stimulation (5.7%), although no patients required lead revision and simply managed by programming changes. The patient demographics of the 175 patients with follow-up and echocardiographic data greater than 1 year are shown in Table 3. The mean follow-up was months. There were no significant differences from the original implant group (Table 1). A comparison between the group predominantly in SR (programmed in a DDDR mode) and the group in persistent/longstanding AF is shown in Table 4. There were no significant differences between the two groups in follow-up duration, age, sex, or comorbid disease. There was a significant difference in both the use of warfarin and the use of amiodarone between the groups in SR and AF (61% and 88%, respectively). Note that the antiarrhythmic drug use reflects usage at the time of implant. The echocardiographic LVEF pre- and post-ablation is shown in Figure 1. The mean LVEF prior to AVN ablation and implantation was 53 12%, and was 58 11% at the end of the follow-up period of months (p5not significant). A comparison of the pre- and post-ablation between the group in SR and AF is depicted in Figure 2. The group predominantly in SR had a mean LVEF prior to implantation of 51 12% and improved to 57 12% (p ). The AF group had a baseline mean LVEF of 56 12% and at follow-up an LVEF of 58 9, but this was not statistically significant (p50.14). Kaplan Meier survival estimates for the total population are graphically depicted in Figure 3. The 1-year survival rates at 1, 3, and 5 years are 97.4%, 87.6%, and 78.0%, respectively. The number of patients at the end of the follow-up period is quite low, with only 34 patients with 60 months of follow-up. In contrast to the significant mortality in this population, the CHF hospitalization-free estimates are shown in Figure 4. There were no CHF admissions during the first 12 months of follow-up, with a total of five admissions over the 60- month period. The event-free rates at 1, 3, and 5 years are 100%, 96.8%, and 92.7%, respectively. Discussion Our data support the use of BiV pacing when performing AVN ablation for symptomatic AF to preserve LV 979 The Journal of Innovations in Cardiac Rhythm Management, October 2012
5 Preservation LVEF and CHF with Ablate and Pace and BiV Pacing Figure 3: Kaplan Meier survival curve total population. function in patients with normal systolic function at baseline who are at risk of developing CHF 4 over a long (37 18 months) duration. Preservation of LV function is seen in patients predominantly in SR or in persistent AF. The acute implant results (Table 2) demonstrate that the procedure can be done safely and with a high initial success rate in an elderly population (mean age 77 years old) without major complications. Although our overall procedure times are short and complication rates low, the data are incomplete and do not demonstrate whether addition of an LV transvenous lead results in increased complications. There was one acute LV lead revision, and the most frequent complication of phrenic nerve stimulation did not require any surgical intervention. This likely represents the increased ability to reprogram pacing vectors in BiV pacemakers even when compared with BiV defibrillators, especially considering the ability to program unipolar pacing. Ablate and pace therapy has been demonstrated previously to cause improvements in both LVEF and exercise tolerance. 1 However, the data from the Ablate and Pace Trial was over a 1-year period. A meta-analysis from the same group demonstrated improved ejection fraction, symptoms, and exercise tolerance at 1 year with a similar mortality to medical therapy. 6 However, this may represent populations with significant improvement in ejection fraction related to tachycardia-mediated cardiomyopathy, and is reflective of short study duration. Previous studies have demonstrated a decrease in LVEF with RV-only pacing and AVN ablation. 7,8 The RV-only group in the PAVE study demonstrated a decrease in overall LVEF at 6 months, but the benefits were seen in patients with a lower baseline ejection fraction. 2 The results are similar in the APAF trial, again with a low baseline LVEF. 3 It is likely that the magnitude of the benefit is greater in the lower LVEF population, while the destabilizing effect of RV-only pacing takes a longer time period to manifest itself. It also seems likely that changes in echocardiographic parameters may be detectable earlier than hospitalizations for heart failure or mortality. The PACE study was able to demonstrate a lower LVEF with RV-only pacing than BiV pacing in patients with preserved LVEF and need for ventricular pacing at 1 year. 4 The high incidence (26%) of newly onset heart failure seen by Zhang et al 5 in patients with acquired AV block was seen over a follow-up period of 7.8 years. While our study cannot make any comparisons with an RV-pacing group, the data are supportive that the preservation of LVEF is maintained over a longer follow-up period. The patient group predominantly in SR showed a statistically significant improvement in LVEF at the end of the follow-up period, while the group in persistent AF showed only a modest improvement that did not reach statistical significance. The group in SR had a lower LVEF at baseline, with virtually identical LVEF in both groups at the end of the follow-up period. We would hypothesize The Journal of Innovations in Cardiac Rhythm Management, October
6 R N Doshi, N Gupta, N Doshi, et al. Study limitations This is a retrospective cohort study, and thus subject to potential bias. There was no control arm, thus not allowing any comparisons with conventional therapy. The data for mortality and CHF admissions were taken from chart review and patient interview, and thus could be incomplete and underestimate the true incidence. Figure 4: Kaplan Meier curve congestive heart failure admissions total population. that this reflects the acute destabilizing effects of paroxysmal AF in the SR population that underwent AVN ablation. Whether or not patients in SR have a greater potential benefit than patients in persistent AF cannot be determined given the potential for selection bias in this retrospective analysis. Based on these studies and others, one would expect a high incidence of heart failure with ablate and pace therapy and conventional RV-only pacing. Tan and colleagues 9 examined 121 patients undergoing ablate and pace therapy with RV-only pacing over a mean follow-up of years. They found a CHF hospitalization rate of 20% and mortality of 26% over the study period despite good control of symptoms. The data presented here compare favorably with a low CHF hospitalization rate over the study period of 7.3% over 5 years. However, the mortality rates are comparable (22% at 5 years), suggesting a different mode of death other than heart failure resulting in hospitalization. In our data set, we did see a high (42%) incidence of severe chronic obstructive pulmonary disease among patients who died during the study period, but we did not characterize modes of death nor was the study powered to make any conclusions. Despite the findings of prior studies of AVN ablation and RV-only pacing, it is still controversial whether or not patients have a clinically significant negative effect in this population. Chen and colleagues 10 have examined their database of patients with echocardiographic data greater than 1 year, and in 152 patients they found no significant decrease in LVEF. However, they did find on multivariate analysis that preserved LVEF was a predictor of decline in function, and the average follow-up period is shorter (20 months) than our study. Bradley and Shen 11 from the same group have reported in a meta-analysis of several trials of ablate and pace therapy, and conclude from their analysis that utilization of BiV pacing may improve results of patients undergoing this procedure, but underscore the lack of controlled randomized data. These reports and our study underscore the importance of a large-scale prospective randomized clinical trial to be performed to determine whether or not this therapy should be utilized in all patients. Conclusions Ablate and pace therapy with BiV pacing or cardiac resynchronization therapy in an elderly population at risk for CHF with symptomatic AF and preserved LV function results in long-term preservation of LV function and low incidence of heart failure hospitalization. A randomized prospective evaluation is warranted to demonstrate conclusively the superiority of this approach when compared with RV pacing or medical therapy long term. References 1. Kay GN, Ellenbogen KA, Giudici M, et al. APT Investigators. J Interv Card Electrophysiol 1998; 2: Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan M, Pires LA for the PAVE Study Group. left ventricular-based cardiac stimulation Post AV Nodal Ablation Evaluation (The PAVE Study). J Cardiovasc Electrophysiol 2005; 16: Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011; 32: Yu CM, Chan JYS, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009; 361: Zhang XH, Chen H, Siu CW, et al. Apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J Cardiovasc Electrophysiol, Feb 2008; 19: Wood MA, Mahoney-Brown C, Kay GN, and Ellenbogen KA. clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 2000; 101: Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344: Twidale N, Manda V, Nave K, Seal A. Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Am Heart J 1998; 136: Tan ES, Rienstra M, Wiesfeld A, Schoonderwoerd BA, Hobbel H, Van Gelder IC. Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. Europace 2008; 10: Chen L, Hodge D, Jahangir A, et al. Preserved Left ventricular ejection fraction following atrioventricular junction and pacing for atrial fibrillation. J Cardiovasc Electrophysiol 2008; 19: Bradley D, Shen W. Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the need for large-scale randomized trials. Heart Rhythm 2007; 4: The Journal of Innovations in Cardiac Rhythm Management, October 2012
Long Term Follow-Up After Atrioventricular Node Ablation and Right Ventricular Pacing: Effects on Clinical Events and Left Ventricular Function
The Open acing, Electrophysiology & Therapy Journal, 2008, 1, 1-5 1 Open Access Long Term Follow-Up After Atrioventricular Node Ablation and Right Ventricular acing: Effects on Clinical Events and Left
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationThoranis Chantrarat MD
Device Therapy in Heart Failure Thoranis Chantrarat MD 1 Scope of presentation Natural history of heart failure Primary and secondary prevention ICD and its indication CRT and its indication 2 Severity
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationTehran Arrhythmia Center
Tehran Arrhythmia Center The Worst Scenario A 4 year old kid High heart rates first noted by parents at 20 months of age. Family physician detected rates as high as 220 bpm at that age. He was visited,
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital
ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital Rate control versus Rhythm control for Atrial Fibrillation AFFIRM N Engl J Med 2002;347:1825-33
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationProgression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro
Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we
More informationDipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese
Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese Because the primary objective was cure symptomatic bradicardya due to syncope Because this is the common
More informationAbstract nr. 1 Abstract code Hybrid Versus Catheter Ablation for Atrial Fibrillation: the HARTCAP-AF Trial
Abstract nr. 1 Hybrid Versus Catheter Ablation for Atrial Fibrillation: the HARTCAP-AF Trial Auteur Vroomen, M., Maastricht University Medical Center, Maastricht, Nederland Co-auteur(s) - La Meir, M. Co-auteur(s)
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationTachycardia-induced heart failure - Does it exist?
Tachycardia-induced heart failure - Does it exist? PD Dr Etienne Delacrétaz Clinique Cecil et Hôpital de Fribourg SSC Cardiology meeting 2015 Zürich Rapid atrial fibrillation is a common cause of heart
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More information5/5/2010. World incidence 720, 000 new cases / year. World prevalence 5.55 million AF prevalence increasing with aging of population
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology UK World incidence 720, 000 new cases / year World prevalence 5.55
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationAtrial Fibrillation: Guidelines through clinical cases and 2010 updates
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology World incidence 720, 000 new cases / year World prevalence 5.5 million
More informationSURVIVAL AFTER ABLATION OF THE ATRIOVENTRICULAR NODE AND IMPLANTATION OF A PERMANENT PACEMAKER
LONG-TERM SURVIVAL AFTER ABLATION OF THE ATRIOVENTRICULAR NODE AND IMPLANTATION OF A PERMANENT PACEMAKER IN PATIENTS WITH ATRIAL FIBRILLATION CEVHER OZCAN, M.D., ARSHAD JAHANGIR, M.D., PAUL A. FRIEDMAN,
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More informationAtrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice Walid Saliba, MD, FHRS Director, Atrial Fibrillation Center Director EP laboratory Heart and Vascular Institute Cleveland
More informationFibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
More informationWide QRS Tachycardia in a Dual Chamber Pacemaker Patient: What is the Mechanism?
CASE REPORTS Arrhythmia 2015;16(3):173-177 doi: http://dx.doi.org/10.18501/arrhythmia.2015.029 Wide QRS Tachycardia in a Dual Chamber Pacemaker Patient: What is the Mechanism? Eun-Sun Jin, MD, PhD Cardiovascular
More informationIn Whom and When Should Atrial Fibrillation Ablation be Considered?
In Whom and When Should Atrial Fibrillation Ablation be Considered? Christian de Chillou, MD, PhD Department of Cardiology University Hospital Nancy, France ESC 2010 Stockholm, August 30. 2010 2 In Whom?
More informationCardiac Resynchronization Therapy: Improving Patient Selection and Outcomes
The Journal of Innovations in Cardiac Rhythm Management, 3 (2012), 899 904 DEVICE THERAPY CLINICAL DECISION MAKING Cardiac Resynchronization Therapy: Improving Patient Selection and Outcomes GURINDER S.
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationCardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing
Cardiac Resynchronisation Therapy for all Patients Requiring Ventricular Pacing Philippe Mabo University Hospital, Rennes, France ESC Congress 2010, Stockholm 29 Aug 2010 Which Patients? Candidate for
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationEffect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin
Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular
More informationCase Report Left Ventricular Dysfunction Caused by Unrecognized Surgical AV block in a Patient with a Manifest Right Free Wall Accessory Pathway
109 Case Report Left Ventricular Dysfunction Caused by Unrecognized Surgical AV block in a Patient with a Manifest Right Free Wall Accessory Pathway Rakesh Gopinathannair, MD, MA 1, Dwayne N Campbell,
More informationCRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?
CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT? Alessandro Lipari, MD Chair and Department of Cardiology University of Study and Spedali Civili Brescia -Italy The birth of CRT in Europe, 20 years ago
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationRuolo della ablazione della fibrillazione atriale nello scompenso cardiaco
Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria
More informationCatheter Ablation for AF: Patients, Procedures, Outcomes
Catheter Ablation for AF: Patients, Procedures, Outcomes John Sapp Director Heart Rhythm, QEII Health Sciences Centre Professor of Medicine, Dalhousie University Atrial Fibrillation Atrial Fibrillation
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationPRESENTER DISCLOSURE INFORMATION. There are no potential conflicts of interest regarding current presentation
PRESENTER DISCLOSURE INFORMATION There are no potential conflicts of interest regarding current presentation Better synchrony and diastolic function for septal versus apical right ventricular permanent
More informationProvocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients
Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients David E. Krummen, MD Associate Professor of Medicine University of California San Diego and VA San Diego Healthcare System
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationManagement of Atrial Fibrillation in Heart Failure
Management of Atrial Fibrillation in Heart Failure Hani Sabbour MD FACC FHRS FASE Clinical Assistant Professor of Cardiology Brown University, Warren Alpert School of Medicine Rhode Island, USA Consultant
More informationA More Definitive Ablation Procedure for Atrial Fibrillation
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/heart-matters/a-more-definitive-ablation-procedure-for-atrialfibrillation/3982/
More informationPVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.
PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More informationΜηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα
Μηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα 2015-2016 Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou has received
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationSUPPLEMENTARY INFORMATION
Table S1 Sex- specific differences in rate- control and rhythm- control strategies in observational studies Study region Study period Total sample size Sex- specific results Ozcan (2001) 1 Mayo Clinic,
More informationEnhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation
Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation Jeff M. Berry, MD and Jose A. Joglar, MD. Department of Internal Medicine (Cardiology),University
More informationRate vs. Rhythm Control in Atrial Fibrillation
Rate vs. Rhythm Control in Atrial Fibrillation Recent Perspectives Saeed Oraii MD Electrophysiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic Delirium Cordis First described by Sir
More informationHow atrial fibrillation should be treated in the heart failure patient?
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze
More informationInterQual Care Planning SIM plus Criteria 2014 Clinical Revisions
InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions The Clinical Revisions provide details of changes to InterQual Clinical Criteria. They do not provide information on changes made to CareEnhance
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationHow Do I Balance Bradycardia with Rate Control in Atrial Fibrillation?
How Do I Balance Bradycardia with Rate Control in Atrial Fibrillation? Thang Nguyen MD FRCPC Assistant Professor Section of Cardiology Department of Internal Medicine University of Manitoba Objectives
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationEBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA
Over 200,000 patients worldwide are estimated to receive a CRT device each year. However, limitations prevent some patients from benefiting. CHALLENGING PROCEDURE 5% implanted patients fail to have coronary
More informationAtrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD
Atrial Fibrillation and Common Supraventricular Tachycardias Sunil Kapur MD Cardiac Electrophysiology Brigham and Women s Hospital Instructor, Harvard Medical School No disclosures Cardiac Conduction:
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationResynchronization/Defibrillation
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial Cardiac Resynchronization Therapy for Mild to Moderate Heart Failure George Wells University of Ottawa Heart Institute Department of
More informationHis Bundle Pacing: Where is it going? Kenneth A. Ellenbogen, M.D. Kontos Professor, VCU School of Medicine November 17, 2017
His Bundle Pacing: Where is it going? Kenneth A. Ellenbogen, M.D. Kontos Professor, VCU School of Medicine November 17, 2017 Conflicts Medtronic: Research, Honoraria, Consulting Boston Scientific: Research,
More informationBi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
More informationCatheter Ablation for Atrial Fibrillation: Patient Selection and Outcomes
Catheter Ablation for Atrial Fibrillation: Patient Selection and Outcomes Francis Marchlinski, MD Richard T and Angela Clark President s Distinguished Professor Director Cardiac Electrophysiolgy University
More informationThe objective of this study was to determine the longterm
The Natural History of Lone Atrial Flutter Brief Communication Sean C. Halligan, MD; Bernard J. Gersh, MBChB, DPhil; Robert D. Brown Jr., MD; A. Gabriela Rosales, MS; Thomas M. Munger, MD; Win-Kuang Shen,
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationHow to Maximize CRT Response?
How to Maximize CRT Response? Chu-Pak Lau, MD Honorary Clinical Professor Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong 1 100% 1/3 of Patients Are Non-Responders of CRT 90%
More informationMission Statement for our Arrhythmia Care
Mission Statement for our Arrhythmia Care We are dedicated to provide a compassionate and an outstanding care for patients with cardiac arrhythmias. We will be utilizing the cutting edge and the most advanced
More informationLong-Term Results of Catheter Ablation in Patients with Drug Refractory Atrial Fibrillation
144 June 2002 Long-Term Results of Catheter Ablation in Patients with Drug Refractory Atrial Fibrillation O. KAL _ EJS, J. JIRGENSONS, J. ANSABERGS, M. BLUMBERGS, N. NESTEROVICS, M. SAUKA, S. SAKNE, M.
More informationCardiac Arrhythmias. Cathy Percival, RN, FALU, FLMI VP, Medical Director AIG Life and Retirement Company
Cardiac Arrhythmias Cathy Percival, RN, FALU, FLMI VP, Medical Director AIG Life and Retirement Company The Cardiovascular System Three primary functions Transport of oxygen, nutrients, and hormones to
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationWhat s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationPractice Questions.
IBHRE Prep Practice Questions Question 1 The relative refractory yperiod of the ventricular myocardium corresponds to which of the following phases of the action potential? A. (0) B. (1) C. (2) D. (3)
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationName of Policy: Transcatheter Ablation of Arrhythmogenic Foci in the Pulmonary Veins as a Treatment of Atrial Fibrillation
Name of Policy: Transcatheter Ablation of Arrhythmogenic Foci in the Pulmonary Veins as a Treatment of Atrial Fibrillation Policy #: 283 Latest Review Date: June 2014 Category: Medical Policy Grade: A
More informationA MULTIDISCIPLINARY APPROACH TO ATRIAL FIBRILLATION: OUR EXPERIENCE WITH THE CONVERGENT PROCEDURE
A MULTIDISCIPLINARY APPROACH TO ATRIAL FIBRILLATION: OUR EXPERIENCE WITH THE CONVERGENT PROCEDURE Joe Aoun, MD Ioannis Koulouridis, MD, MSc Aleem Mughal, MD Maxwell Eyram Afari, MD Caroline Zahm, MD John
More informationProf. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.
Obesity as a risk factor for Atrial Fibrillation Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept. CardioAlex 2010 smrafla@hotmail.com 1 Obesity has reached epidemic proportions in the United
More informationImproving Patient Outcomes with a Syncope Center. Suneet Mittal, MD
Improving Patient Outcomes with a Syncope Center Suneet Mittal, MD Improving Patient Outcomes with a Syncope Center: Early Risk Stratification of Patients who Require Device Therapy Suneet Mittal, MD Director,
More informationBrian Olshansky, MD, FHRS,* John D. Day, MD, FHRS, Renee M. Sullivan, MD,* Patrick Yong, MSEE, Elizabeth Galle, MS, Jonathan S. Steinberg, MD, FHRS
Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: An analysis from the COMPANION Trial Brian
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationCardiac Resynchronization in Patients With Atrial Fibrillation
Journal of the American College of Cardiology Vol. 52, No. 15, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.06.043
More informationA Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE
A Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE Adele Greyling Dora Nginza Hospital, Port Elizabeth SA Heart November 2017 What are the guidelines based on? MADIT-II Size:
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationSCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA
Journal Club 19 Marzo 2010 SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA Alessandro Giordano Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007 Incidence of heart failure by age
More informationTranscoronary Chemical Ablation of Atrioventricular Conduction
757 Transcoronary Chemical Ablation of Atrioventricular Conduction Pedro Brugada, MD, Hans de Swart, MD, Joep Smeets, MD, and Hein J.J. Wellens, MD In seven patients with symptomatic atrial fibrillation
More information2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist
2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist Todays Objectives Atrial Fibrillation evaluation and treatment from an EP perspective Multimodal
More informationDECREASE-HF CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY DECREASE-HF Boston Scientific Corporation
More informationUpgrade to Resynchronization Therapy. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016
Upgrade to Resynchronization Therapy Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016 Event Free Survival (%) CRT Cardiac resynchronization therapy (CRT)
More informationGuideline Number: NIA_CG_320 Last Revised Date: July, 2018 Responsible Department: Implementation Date: January 2019 Clinical Operations
National Imaging Associates, Inc. Clinical guidelines CARDIAC RESYNCHRONIZATION THERAPY (CRT) CPT Codes: 33221, 33224, 33225, 33231 Original Date: February, 2013 Page 1 of 10 Last Review Date: March 2017
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationEHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
More informationThe Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy
The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy Results from the SMART-AV Trial Michael R. Gold, MD, PhD, Ulrika Birgersdotter-Green,
More informationLong-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation
Long-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation Carlo Pappone, MD, PhD, FACC EP Director, Villa Maria Hospital Group How many times AF can increase mortality DO MORTALITY REALLY
More informationPERFORMANCE MEASURE TECHNICAL SPECIFICATIONS. HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate
PERFORMANCE MEASURE TECHNICAL SPECIFICATIONS HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate Measure Title Description Measure Type Data Source Level of Analysis Numerator HRS-3:
More informationAtrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA
More information